IFNL4 rs368234815 and rs117648444 variants predict off‐treatment HBsAg seroclearance in IFN‐treated HBeAg‐negative chronic hepatitis B patients

Publisher： John Wiley & Sons Inc

E-ISSN： 1478-3231|38|3|417-423

ISSN： 1478-3223

Source： LIVER INTERNATIONAL (ELECTRONIC), Vol.38, Iss.3, 2018-03, pp. : 417-423

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Precore/Core promoter variants to predict significant fibrosis in both HBeAg positive and negative chronic hepatitis B

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 9, 2015-09 ,pp. : 2082-2089

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long‐term outcome in Caucasian patients with chronic hepatitis B virus infection after HBsAg seroclearance

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 1, 2015-01 ,pp. : 140-147

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long-Term Presence of HBV in the Sera of Chronic Hepatitis B Patients with HBsAg Seroclearance

By  

Intervirology, Vol. 50, Iss. 3, 2007-01 ,pp. : 161-165

Karger

Access to resources Recommend Favorite

On‐treatment prediction of sustained response to peginterferon alfa‐2a for HBeAg‐negative chronic hepatitis B patients

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 5, 2015-05 ,pp. : 1540-1548

John Wiley & Sons Inc

Access to resources Recommend Favorite

HBsAg loss is not an ideal indicator for discontinuing treatment of HBeAg-negative chronic hepatitis B: a case report

By Dong Pei-ling   Zhang Xin   Zhao Wen-min   Ding Hui-guo  

Journal of Infection and Chemotherapy, Vol. 19, Iss. 6, 2013-12 ,pp. : 1188-1192

Springer Publishing Company

Access to resources Recommend Favorite